US · 1 entry · 1 publication
Boston Scientific Corp
No entry states a stance.
Free during launch: log in or sign up with your email to see it.
Sign up freeSubstack · The Global Gambit's Substack · The Global Gambit
Reduced earnings targets, competitive pressures, and summer seasonality signal a cooling trajectory for the medical device maker following a record Q2.
Since publication +7.5% α +8.8 pp vs S&P 500 · USD
There is 1 more low-confidence entry, hidden because the ticker could not be checked in the text. See them in the index →
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.